<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dig Dis Sci</journal-id><journal-id journal-id-type="iso-abbrev">Dig Dis Sci</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Digestive Diseases and Sciences</journal-title></journal-title-group><issn pub-type="ppub">0163-2116</issn><issn pub-type="epub">1573-2568</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10635943</article-id><article-id pub-id-type="pmcid-ver">PMC10635943.1</article-id><article-id pub-id-type="pmcaid">10635943</article-id><article-id pub-id-type="pmcaiid">10635943</article-id><article-id pub-id-type="pmid">37864738</article-id><article-id pub-id-type="doi">10.1007/s10620-023-08043-8</article-id><article-id pub-id-type="publisher-id">8043</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bangaru</surname><given-names initials="S">Saroja</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sundaresh</surname><given-names initials="R">Ram</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="A">Anna</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prause</surname><given-names initials="N">Nicole</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hao</surname><given-names initials="F">Frank</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="TS">Tien S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tincopa</surname><given-names initials="M">Monica</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cholankeril</surname><given-names initials="G">George</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rich</surname><given-names initials="NE">Nicole E.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawamoto</surname><given-names initials="J">Jenna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names initials="D">Debika</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="SB">Steven B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="AA">Arpan A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shaheen</surname><given-names initials="M">Magda</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2442-5145</contrib-id><name name-style="western"><surname>Benhammou</surname><given-names initials="JN">Jihane N.</given-names></name><address><email>jbenhammmou@mednet.ucla.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Vatche and Tamar Manoukian Division of Digestive Diseases, </institution><institution>David Geffen School of Medicine at the University of California, Los Angeles, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.417119.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0384 5381</institution-id><institution>Greater Los Angeles Veterans Affairs Healthcare System, Gastroenterology, Hepatology and Parenteral Nutrition, </institution></institution-wrap>Los Angeles, CA 90075 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>David Geffen School of Medicine, </institution><institution>University of California, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Department of Radiology, </institution><institution>University of California, Los Angeles, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Liver Center, </institution><institution>University of California, San Diego, </institution></institution-wrap>San Diego, CA 92093 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pttbw34</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Section of Gastroenterology and Hepatology, Department of Medicine, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX 77030 USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t9vx427</institution-id><institution-id institution-id-type="GRID">grid.416214.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0446 6131</institution-id><institution>UT Southwestern Medical Center, </institution><institution>Division of Digestive and Liver Diseases and Harold C. Simmons Comprehensive Cancer Center, </institution></institution-wrap>Dallas, TX 75390 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Division of Infectious Diseases, </institution><institution>David Geffen School of Medicine at the University of California, Los Angeles, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.417119.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0384 5381</institution-id><institution>Section of Infectious Diseases, </institution><institution>Greater Los Angeles Veterans Affairs Healthcare System, </institution></institution-wrap>Los Angeles, CA 90075 USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.428235.a</institution-id><institution>VA Center for the Study of Healthcare Innovation, Implementation, and Policy (CSHIIP), </institution></institution-wrap>North Hills, CA 91343 USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gds4h28</institution-id><institution-id institution-id-type="GRID">grid.255236.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2290 3196</institution-id><institution>College of Medicine, </institution><institution>Charles R Drew University, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Jonsson Comprehensive Cancer Center, </institution><institution>University of California, Los Angeles, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution>Department of Medicine, </institution><institution>University of California, Los Angeles, </institution></institution-wrap>11301 Wilshire Blvd, Building 113, Room 312, Los Angeles, CA 90073 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>68</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">448885</issue-id><fpage>4474</fpage><lpage>4484</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>11</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-27 02:25:09.820"><day>27</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10620_2023_Article_8043.pdf"/><abstract id="Abs1"><sec><title>Background and Aims</title><p id="Par1">Nonalcoholic fatty liver disease (NAFLD) has reached pandemic proportions. Early detection can identify at-risk patients who can be linked to hepatology care. The vibration-controlled transient elastography (VCTE) controlled attenuation parameter (CAP) is biopsy validated to diagnose hepatic steatosis (HS). We aimed to develop a novel clinical predictive algorithm for HS using the CAP score at a Veterans&#8217; Affairs hospital.</p></sec><sec><title>Methods</title><p id="Par2">We identified 403 patients in the Greater Los Angeles VA Healthcare System with valid VCTEs during 1/2018&#8211;6/2020. Patients with alcohol-associated liver disease, genotype 3 hepatitis C, any malignancies, or liver transplantation were excluded. Linear regression was used to identify predictors of NAFLD. To identify a CAP threshold for HS detection, receiver operating characteristic analysis was applied using liver biopsy, MRI, and ultrasound as the gold standards.</p></sec><sec><title>Results</title><p id="Par3">The cohort was racially/ethnically diverse (26% Black/African American; 20% Hispanic). Significant positive predictors of elevated CAP score included diabetes, cholesterol, triglycerides, BMI, and self-identifying as Hispanic. Our predictions of CAP scores using this model strongly correlated (<italic toggle="yes">r</italic>&#8201;=&#8201;0.61, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) with actual CAP scores. The NAFLD model was validated in an independent Veteran cohort and yielded a sensitivity of 82% and specificity 83% (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, 95% CI 0.46&#8211;0.81%). The estimated optimal CAP for our population cut-off was 273.5&#160;dB/m, resulting in AUC&#8201;=&#8201;75.5% (95% CI 70.7&#8211;80.3%).</p></sec><sec><title>Conclusion</title><p id="Par4">Our HS predictive algorithm can identify at-risk Veterans for NAFLD to further risk stratify them by non-invasive tests and link them to sub-specialty care. Given the biased referral pattern for VCTEs, future work will need to address its applicability in non-specialty clinics.</p></sec><sec><title>Graphical Abstract</title><p id="Par5">Proposed clinical algorithm to identify patients at-risk for NAFLD prior to fibrosis staging in Veteran.
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1" orientation="portrait" xlink:href="10620_2023_8043_Figa_HTML.jpg"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10620-023-08043-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nonalcoholic fatty liver disease</kwd><kwd>Prediction</kwd><kwd>Model</kwd><kwd>Elastography</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>UL1TR001881</award-id><principal-award-recipient><name name-style="western"><surname>Benhammou</surname><given-names>Jihane N.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Nonalcoholic fatty liver disease (NAFLD) has reached pandemic proportions, currently affecting 25&#8211;30% of the United States population [<xref ref-type="bibr" rid="CR1">1</xref>]. An estimated 2 million Veterans (30%) have NAFLD, with the prevalence nearly tripling in recent years [<xref ref-type="bibr" rid="CR2">2</xref>]. NAFLD encompasses a spectrum of liver disease including hepatic steatosis (HS) and its more severe form, nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Patients with NAFLD are also at an increased risk of non-hepatic complications, including cardiovascular events [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], extrahepatic malignancies [<xref ref-type="bibr" rid="CR5">5</xref>], and overall poor quality of life [<xref ref-type="bibr" rid="CR6">6</xref>]. As NASH-related cirrhosis is becoming the leading indication for liver transplantation [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], early disease detection is critical.</p><p id="Par7">However, diagnosing NAFLD in its early stages remains a challenge. In routine clinical care, HS incidentally found on imaging with or without elevated transaminases, rather than recognition of metabolic comorbidities as part of a dedicated evaluation, prompts referral to hepatology/gastroenterology clinics for further evaluation of NAFLD. Liver biopsy (LB) remains the diagnostic gold standard which is limited by cost, sampling error, and procedural risks [<xref ref-type="bibr" rid="CR9">9</xref>], preventing its implementation at a population scale and restricting its use primarily to clinical trials [<xref ref-type="bibr" rid="CR10">10</xref>]. To address this challenge, in 2021, the American Gastroenterology Association (AGA) developed guidelines that encourage primary care providers to recognize and screen patients at risk of NAFLD defined as having (1) at least 2 metabolic risk factors (obesity, hypertriglyceridemia, low high-density lipoprotein-HDL, and hypertension or prediabetes), (2) type 2 diabetes (diabetes), or (3) elevated transaminases [<xref ref-type="bibr" rid="CR11">11</xref>]. However, given the large burden of NAFLD coupled with competing clinical responsibilities during primary care visits, developing easily applicable, automated algorithms embedded in electronic health records (EHR) to identify at-risk patients can facilitate early detection.</p><p id="Par8">Vibration-controlled transient elastography (VCTE, FibroScan&#174;) can estimate liver stiffness and HS noninvasively [<xref ref-type="bibr" rid="CR12">12</xref>]. The VCTE controlled attenuation parameter (CAP) has been validated in HS diagnosis in several prospective biopsy-controlled studies that report excellent diagnostic accuracy for HS detection [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. It is therefore gaining traction as a non-invasive method of risk-stratifying chronic liver disease. Further, HS as measured by the CAP score is associated with an increased overall mortality in the United States, independent of hepatic fibrosis [<xref ref-type="bibr" rid="CR18">18</xref>]. Despite its advantages, implementation of VCTE has challenges: it is not always available to all clinics; it requires additional training in its interpretation; and most importantly, it has not been shown to be cost effective in an initial assessment of patients at risk for NAFLD. [<xref ref-type="bibr" rid="CR19">19</xref>]</p><p id="Par9">The Veterans Affairs Healthcare System (VAHCS) is the largest integrated health system in the United States with long-term longitudinal clinical and demographic data. Despite the growing burden of NAFLD among Veterans, Veterans Health Administration (VHA)-based NAFLD predictive algorithms are lacking [<xref ref-type="bibr" rid="CR20">20</xref>]. Given that VCTE is becoming the standard of care in clinical practice [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and the unique VHA EHR offers, we aimed to develop a clinical predictive algorithm using the VCTE CAP score to identify at-risk Veterans for NAFLD.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data Source</title><p id="Par10">The study was approved by the Veterans Affairs Institutional Review Board. VCTE was introduced to the VA Greater Los Angeles Healthcare System (VAGLAHS) in 03/2016 for assessment of hepatic fibrosis. In 01/2017, the CAP was introduced for HS measurement. We queried the Corporate Data Warehouse, a repository of all clinical health data at VAGLAHS, from 01/2017 to 0/62020.</p></sec><sec id="Sec4"><title>Discovery Cohort</title><p id="Par11">At VAGLAHS, 1,767 VCTE records were available between 01/2016 and 06/2020, of which 1,403 had a CAP score. As VCTE is operator dependent and requires training for proficiency [<xref ref-type="bibr" rid="CR22">22</xref>], we selected cases from 2018 to 2020 to allow enough time for operators to become proficient. Three trained navigators (S.B., R.S., A.L.) abstracted clinical data from the EHR using a common data abstraction form after being trained by the same person (S.B). Near the end of data abstraction, one primary clinician abstractor (S.B.) reviewed a 20% random sample from each abstractor&#8217;s data sample to assure accuracy of data. The study team discussed and resolved any discrepancies by consensus. This resulted in 740 unique patients with VCTE reports. Exclusion criteria were as follows: high-risk ethanol use (any AUDIT-C&#8201;&gt;&#8201;3 in women or&#8201;&gt;&#8201;4 for men [<xref ref-type="bibr" rid="CR20">20</xref>] or with a diagnosis of alcohol-associated liver disease (ALD) made by a hepatologist); chronic HCV genotype 3 (<italic toggle="yes">n</italic>&#8201;=&#8201;4), given its competing cause of HS; patients with a history of primary or secondary liver malignancy or who had a liver transplantation were also excluded; and VCTE reports with poor technical quality (liver stiffness measurement interquartile range (IQR)&#8201;&gt;&#8201;30% [<xref ref-type="bibr" rid="CR23">23</xref>]), resulting in 434 patients. Patients lacking any radiographic or LB data were also excluded, yielding a final discovery cohort of 403 patients (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study Population</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10620_2023_8043_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Data Collection</title><p id="Par12">Socio-demographic and clinical information were collected from the EHR including age, sex, race, ethnicity, hepatitis B surface antigen, hepatitis C antibody, hepatitis C RNA, human immunodeficiency virus (HIV) antibody, and antiviral treatment history (hepatitis B and C); body mass index (BMI) and systolic and diastolic blood pressures on the date of VCTE; and whether patients had active prescriptions for anti-hypertensives, statins, or for diabetes medications at the time of VCTE. Laboratory parameters including white blood cell count, platelet count, ALT, aspartate aminotransferase (AST), alkaline phosphatase (AP), total bilirubin, lipid panel, hemoglobin A1c, random glucose, and lipid panel were also obtained. All laboratory parameters were collected on dates closest to the VCTE date and no more than 1&#160;year from the VCTE date. All VCTE (Fibroscan&#174; 502 touch) reports were reviewed. CAP score, LSM with IQR, and probe size (M or XL) were obtained from each VCTE report.</p></sec><sec id="Sec6"><title>Selection of Covariables</title><p id="Par13">Covariables were selected a priori based on previous NAFLD algorithms, considering both biological plausibility and clinical availability. We included age, sex, and race, and ethnicity due to prior studies describing their associations [<xref ref-type="bibr" rid="CR24">24</xref>]. Given that many of the clinical and laboratory variables were part of the metabolic syndrome, multicollinearity was evaluated prior to final covariable selection (Supplementary Fig.&#160;2). Patients who were prescribed statin medications exhibited a significantly lower low-density lipoprotein (LDL) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Supplementary Fig.&#160;3), so we avoided inclusion of both LDL and use of statin because of the anticipated causal relationship. We assessed the effect of anti-hypertensive medication prescription rather than blood pressure measurement, given that single random blood pressure on the day of the VCTE may not accurately capture a clinical diagnosis of hypertension. For diabetes, because having an active prescription for diabetes medication did not have the predicted relationship with hemoglobin A1c (being on treatment for was associated with higher hemoglobin A1c, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Supplementary Fig.&#160;4), we defined diabetes as a hemoglobin A1c&#8201;&gt;&#8201;6.5% or having a diabetes medication prescription. We considered including HDL, triglycerides and BMI as components of metabolic syndrome, consistent with the National Heart, Lung, and Blood Institute (NHLBI) definition and given the AGA Clinical Care Pathway guidance statement (see Introduction). Given that triglycerides are commonly defined in the NHLBI metabolic syndrome definition, they were selected for inclusion over HDL. ALT and AST demonstrated a high correlation (<italic toggle="yes">r</italic>&#8201;=&#8201;0.81), and given the association between ALT and NAFLD in previous work [<xref ref-type="bibr" rid="CR20">20</xref>], ALT alone was selected for inclusion.</p></sec><sec id="Sec7"><title>Validation Cohort</title><p id="Par14">To validate the predicted NAFLD clinical definition and CAP score, we identified 40 unique Veterans in 2017&#8211;2021. VCTE reports and either imaging (US or MRI) or LB were available for all 40 patients (see Statistical Analysis for power calculation).</p></sec><sec id="Sec8"><title>Imaging Data</title><p id="Par15">US and MRI abdomen were reviewed centrally for the presence or absence of HS, by a single expert abdominal radiologist (F.H.) who was blinded to the remainder of the data and statistical analysis. Of note, only 7 MRI with elastography with PDFF to quantitate HS were available and included in our cohort (MRE was introduced after VCTE at GLA). HS on MRI was identified using T1-weighted gradient-echo in-phase and&#160;out-of-phase sequences. If there was signal drop out in the out-of-phase sequence compared to in-phase, then HS was diagnosed. Computerized tomography imaging data were excluded because of its limited accuracy in HS diagnosis [<xref ref-type="bibr" rid="CR25">25</xref>]. All imaging data were obtained at the time closest to the VCTE date, with median time of 8.2&#160;weeks for US and 2.1&#160;weeks for MRI. Of note, 3 abdominal USs were conducted outside our local VA including through community care, which were not able to be reviewed locally.</p></sec><sec id="Sec9"><title>Liver Biopsy</title><p id="Par16">LB pathology reports were reviewed when available. The presence or absence of HS was recorded as a binary variable and included any grade of steatosis. Of note, NAFLD activity score was not clinically utilized.</p></sec><sec id="Sec10"><title>Statistical Analysis</title><sec id="Sec11"><title>Covariable Descriptions</title><p id="Par17">Patient demographics and clinical parameters were summarized by mean&#8201;&#177;&#8201;standard deviation (SD) for continuous variables and frequency (%) for categorical variables.</p></sec><sec id="Sec12"><title>Power Calculation for Validation Cohort</title><p id="Par18">To test the fit of our 6-predictor regression, assuming the tests for total regression with <italic toggle="yes">R</italic><sup>2</sup>&#8201;=&#8201;0.35 (<italic toggle="yes">F</italic><sup>2</sup>&#8201;=&#8201;0.55), <italic toggle="yes">n</italic>&#8201;=&#8201;29 patients were needed for a power of 80% and a significance of 0.05.</p></sec><sec id="Sec13"><title>Development and Performance of NAFLD Definition</title><p id="Par19">Multivariable linear regression modeling using CAP score as a continuous variable and backward elimination of covariables to determine significant predictors of HS. Specifically, the &#8220;caret&#8221; library in R was used to implement the leave-one-out, cross-validation approach, which offers more stable estimates in high-dimension, small sample data. To evaluate the performance of our NAFLD definition, we determined the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We calculated the correlation between predicted and actual CAP scores.</p></sec><sec id="Sec14"><title>Determination of CAP Threshold</title><p id="Par20">Given the heterogeneity in steatosis thresholds across different populations [<xref ref-type="bibr" rid="CR26">26</xref>], we developed an internally validated CAP threshold that distinguishes presence or absence HS in Veterans. We defined the HS using a hierarchical composite algorithm where all available LBs were selected first (classified as positive or negative for any grade of HS), followed by all unique MRIs (classified as positive or negative for HS), and finally unique US (classified as positive or negative HS). Agreement between the test results for LB, MRI, and US were explored using Cohen&#8217;s kappa. Associations between CAP score and each of LB, MRI, and US were explored using unpaired <italic toggle="yes">t</italic> tests. Receiver operating characteristic (ROC) analysis was used to determine the Veteran-specific CAP cut-off using our HS definition as a binary variable. When results occasionally conflicted, the result from the more accurate test was used, as defined by LB, followed by MRI, and then US. Each patient was only counted once. We identified 31 patients without a LB, MRI, or US. Since CAP scores of the 31 patients ranged from no HS to severe steatosis [<xref ref-type="bibr" rid="CR27">27</xref>] (Supplementary Fig.&#160;1), they were excluded from our final cohort (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The optimal CAP threshold for HS detection was selected using the Youden method. The ROC curve was plotted using R 4.1 library pROC. The optimal cut-off was identified using library cutpointr function &#8220;oc_youden_kernel,&#8221; which maximizes both sensitivity and specificity on the ROC curve after smoothing of the predictor by a binned kernel density estimate. <italic toggle="yes">p</italic> values are from 2-sided tests with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 considered statistically significant. Analyses was completed in R 4.1.2.</p></sec></sec></sec><sec id="Sec15"><title>Results</title><sec id="Sec16"><title>Demographic and Clinical Characteristics</title><p id="Par21">Four-hundred and thirty-four patients met our inclusion criteria (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Of these, 403 had at least one of LB, MRI, or US available for inclusion in CAP threshold development (Table <xref rid="Tab1" ref-type="table">1</xref>). All 403 patients had a complete set of pre-selected predictors. The mean age was 60.1&#8201;&#177;&#8201;13.4&#160;years. The cohort was predominantly male (96.8%, <italic toggle="yes">n</italic>&#8201;=&#8201;390) and was racially and ethnically diverse, with African American/Black race representing 26.1% (<italic toggle="yes">n</italic>&#8201;=&#8201;105) and Hispanic ethnicity constituting 19.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;78) of the cohort. Most patients had features of the metabolic syndrome: 53.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;215) were on anti-hypertensive medications; 34.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;137) were on diabetes treatment; and 51.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;205) were prescribed a statin. The median CAP score in our cohort was 286.5&#160;dB/m (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a). The median LSM was 6.6&#160;kPa, with the majority (<italic toggle="yes">n</italic>&#8201;=&#8201;295, 73.2%) of patients with early stage (F0&#8211;F2) fibrosis and were therefore less likely to have &#8220;burnt-out&#8221; NASH [<xref ref-type="bibr" rid="CR28">28</xref>] (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>b). Of the patients with&#8201;&#8805;&#8201;20&#160;kPa (<italic toggle="yes">n</italic>&#8201;=&#8201;39), 51% had CAP&#8201;&gt;&#8201;274&#160;dB/m (mean 280.5&#160;dB/m). This was consistent with largely preserved synthetic liver function, evidenced by mean total bilirubin of 0.8&#8201;&#177;&#8201;0.4&#160;mg/dL and mean platelet count of 210.6&#8201;&#215;&#8201;10<sup>9</sup>/L, suggestive of no clinically significant portal hypertension.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient and clinical demographics of cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;403)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Socio-demographic characteristics</th><th align="left" colspan="1" rowspan="1">Average (SD) or count (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td char="(" align="char" colspan="1" rowspan="1">60.1 (13.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male sex</td><td char="(" align="char" colspan="1" rowspan="1">390 (96.8)</td></tr><tr><td align="left" colspan="2" rowspan="1">Race</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;White</td><td char="(" align="char" colspan="1" rowspan="1">218 (54.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Black or African American</td><td char="(" align="char" colspan="1" rowspan="1">105 (26.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asian</td><td char="(" align="char" colspan="1" rowspan="1">35 (8.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Declined to answer</td><td char="(" align="char" colspan="1" rowspan="1">34 (8.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;American Indian/Alaska Native</td><td char="(" align="char" colspan="1" rowspan="1">6 (1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Another race not listed</td><td char="(" align="char" colspan="1" rowspan="1">3 (0.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Native Hawaiian or Other Pacific Islander</td><td char="(" align="char" colspan="1" rowspan="1">2 (0.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Ethnicity</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not Hispanic</td><td char="(" align="char" colspan="1" rowspan="1">305 (75.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hispanic</td><td char="(" align="char" colspan="1" rowspan="1">79 (19.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Declined to answer or not available</td><td char="(" align="char" colspan="1" rowspan="1">19 (4.7)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical characteristics</th><th align="left" colspan="1" rowspan="1">Average (SD) or count (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#160;Hepatitis C (antibody)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Positive</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Sustained virologic response&#160;(SVR)</td><td align="left" colspan="1" rowspan="1">59 (14.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not post-treatment</td><td align="left" colspan="1" rowspan="1">68 (16.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">275 (68.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not available</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="2" rowspan="1">Hepatitis B surface antigen</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">20 (5.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">374 (92.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not available</td><td align="left" colspan="1" rowspan="1">9 (2.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Human immunodeficiency virus (HIV) positive antibody</td><td align="left" colspan="1" rowspan="1">6 (1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Body Mass Index (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">30.5 (6.0)</td></tr><tr><td align="left" colspan="2" rowspan="1">Active prescription for treatment of</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Diabetes mellitus (medication or A1c&#8201;&gt;&#8201;6.5%)</td><td align="left" colspan="1" rowspan="1">137 (34.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hyperlipidemia (statin)</td><td align="left" colspan="1" rowspan="1">205 (51.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hypertension (any anti-hypertensive)</td><td align="left" colspan="1" rowspan="1">215 (53.5%)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Laboratory parameters</th><th align="left" colspan="1" rowspan="1">Average (SD)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Alanine aminotransferase (U/L)</td><td align="left" colspan="1" rowspan="1">45.1 (46.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Aspartate aminotransferase (U/L)</td><td align="left" colspan="1" rowspan="1">34.4 (22.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alkaline phosphatase (U/L)</td><td align="left" colspan="1" rowspan="1">83.9 (43.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total bilirubin (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.8 (0.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">164.8 (46.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Random glucose (mmol/L)</td><td align="left" colspan="1" rowspan="1">125.1 (50.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelets (/microL)</td><td align="left" colspan="1" rowspan="1">210.6 (67.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin A1c (%)</td><td align="left" colspan="1" rowspan="1">6.3 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL (mmol/L)</td><td align="left" colspan="1" rowspan="1">92.6 (39.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL (mmol/L)</td><td align="left" colspan="1" rowspan="1">43.1 (11.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglyceride (mmol/L)</td><td align="left" colspan="1" rowspan="1">154.2 (120.2)</td></tr></tbody></table></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>CAP and fibrosis distribution of cohort based on VCTE (<italic toggle="yes">n</italic>&#8201;=&#8201;403)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10620_2023_8043_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>NAFLD Predictors and Model Performance</title><sec id="Sec18"><title>Model Development</title><p id="Par22">Our regression analysis included the following covariables: age, sex, race, ethnicity, statin prescription, anti-hypertensive prescription, ALT, triglycerides, cholesterol, diabetes, and BMI. After stepwise variable selection and cross-validation, the optimal linear multivariate model identified had 6 predictors <italic toggle="yes">F</italic>(6, 387)&#8201;=&#8201;37.8, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}_{\mathrm{adj}}^{2}$$\end{document}</tex-math><mml:math id="M2"><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="normal">adj</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq1.gif"/></alternatives></inline-formula>&#160;=&#160;0.36 (Supplementary Fig.&#160;5). The 6 predictors included African American/Black race, Hispanic ethnicity, cholesterol, diabetes, BMI, and triglycerides (Table <xref rid="Tab2" ref-type="table">2</xref>). Consistent with previous work [<xref ref-type="bibr" rid="CR24">24</xref>], we found a significant positive association between CAP scores and patients who self-identified as Hispanic (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Supplementary Fig.&#160;6) and a significant negative association between self-identifying as African American/Black and CAP scores (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Supplementary Fig.&#160;6). The final NAFLD definition derived from the multivariable model was as follows:<disp-formula id="Equa"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \widehat{CAP} = &amp; {75}.{67} + \left( { - {26}.{6} \times {\text{Black}}} \right) + \left( {{13}.{7} \times {\text{Hispanic}}} \right) + \left( {0.{15} \times {\text{Cholesterol}}} \right) + \left( {{5}.{3} \times {\text{BMI}}} \right) \\ &amp;\quad+ \left( {{32}.0 \times {\text{Diabetes}} - {\text{Prescription}}\;{\text{or}}\;{\text{high}}\;{\text{A1c}}} \right) + \left( {0.0{6} \times {\text{Triglycerides}}} \right) \\ \end{aligned}.$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi mathvariant="italic">CAP</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mn>75.67</mml:mn><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mo>-</mml:mo><mml:mn>26.6</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>Black</mml:mtext></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>13.7</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>Hispanic</mml:mtext></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.15</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>Cholesterol</mml:mtext></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>5.3</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>BMI</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow/></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="1em"/><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>32.0</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>Diabetes</mml:mtext><mml:mo>-</mml:mo><mml:mtext>Prescription</mml:mtext><mml:mspace width="0.277778em"/><mml:mtext>or</mml:mtext><mml:mspace width="0.277778em"/><mml:mtext>high</mml:mtext><mml:mspace width="0.277778em"/><mml:mtext>A1c</mml:mtext></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0.06</mml:mn><mml:mo>&#215;</mml:mo><mml:mtext>Triglycerides</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow/></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="10620_2023_8043_Article_Equa.gif"/></alternatives></disp-formula><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Significant clinical predictors of CAP scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Predictor</th><th align="left" colspan="1" rowspan="1"><inline-formula id="IEq8"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\beta$$\end{document}</tex-math><mml:math id="M6"><mml:mi>&#946;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq8.gif"/></alternatives></inline-formula></th><th align="left" colspan="1" rowspan="1"><inline-formula id="IEq9"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{\mathrm{std}}$$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mi>&#946;</mml:mi><mml:mi mathvariant="normal">std</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq9.gif"/></alternatives></inline-formula></th><th align="left" colspan="2" rowspan="1">CI</th><th align="left" colspan="1" rowspan="1"><inline-formula id="IEq10"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\eta }_{p}^{2}$$\end{document}</tex-math><mml:math id="M10"><mml:msubsup><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq10.gif"/></alternatives></inline-formula></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Body mass index</td><td char="." align="char" colspan="1" rowspan="1">5.3</td><td char="." align="char" colspan="1" rowspan="1">0.43</td><td char="." align="char" colspan="1" rowspan="1">4.3</td><td char="." align="char" colspan="1" rowspan="1">6.3</td><td char="." align="char" colspan="1" rowspan="1">0.23</td></tr><tr><td align="left" colspan="1" rowspan="1">Black or African American*</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#160;26.6</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#160;0.16</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#160;40.7</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#160;12.6</td><td char="." align="char" colspan="1" rowspan="1">0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes Mellitus (med or A1c&#8201;&gt;&#8201;6.5%)</td><td char="." align="char" colspan="1" rowspan="1">32.0</td><td char="." align="char" colspan="1" rowspan="1">0.21</td><td char="." align="char" colspan="1" rowspan="1">45.0</td><td char="." align="char" colspan="1" rowspan="1">19.1</td><td char="." align="char" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">Hispanic*</td><td char="." align="char" colspan="1" rowspan="1">13.7</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">&#8722;&#160;1.7</td><td char="." align="char" colspan="1" rowspan="1">29.1</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol</td><td char="." align="char" colspan="1" rowspan="1">0.15</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td char="." align="char" colspan="1" rowspan="1">0.3</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglycerides</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td char="." align="char" colspan="1" rowspan="1">0.1</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr></tbody></table><table-wrap-foot><p>6-predictor model <italic toggle="yes">F</italic>(6, 387)&#8201;=&#8201;37.8, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;.001, <inline-formula id="IEq11"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}_{\mathrm{adj}}^{2}$$\end{document}</tex-math><mml:math id="M12"><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="normal">adj</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq11.gif"/></alternatives></inline-formula>&#160;=&#160;0.36;</p><p>*White was used as the reference group</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec19"><title>Model Performance in Discovery Cohort</title><p id="Par23">We used our NAFLD predictive equation to calculate a predicted CAP (<inline-formula id="IEq2"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M14"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq2.gif"/></alternatives></inline-formula>) score for each patient. <inline-formula id="IEq3"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M16"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq3.gif"/></alternatives></inline-formula> and CAP were significantly correlated (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, 95% CI 0.54&#8211;0.67; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). We further evaluated the performance of our predictive model within our Veteran cohort using our internally developed CAP threshold of 273.5&#160;dB/m. <inline-formula id="IEq4"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M18"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq4.gif"/></alternatives></inline-formula> was classified as above or below 273.5&#160;dB/m (see above) and compared to actual CAP as above or below 273.5&#160;dB/m. The sensitivity, specificity, NPV, and PPV for our model to identify HS as defined by CAP&#8201;&gt;&#8201;273.5&#160;dB/m were 77%, 76%, 72%, and 80%, respectively.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Relationship of CAP predicted by formula and measured CAP</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10620_2023_8043_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec20"><title>Model Performance in Validation Cohort</title><p id="Par24">We used our NAFLD predictive equation to calculate a predicted CAP score for each patient in the validation cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;40) (Supplementary Table 3). CAP and <inline-formula id="IEq5"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M20"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq5.gif"/></alternatives></inline-formula> were significantly correlated (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, 95% CI 0.46&#8211;0.81; see Supplement Figs.&#160;7 and 10). We again classified <inline-formula id="IEq6"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M22"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq6.gif"/></alternatives></inline-formula> and actual CAP for each patient as above or below 273.5&#160;dB/m and compared them. The sensitivity, specificity, NPV, and PPV for our model to identify HS as defined by CAP&#8201;&gt;&#8201;273.5&#160;dB/m were 82%, 83%, 86%, and 78%, respectively.</p></sec></sec><sec id="Sec21"><title>Development of Internally Validated CAP Threshold</title><sec id="Sec22"><title>Associations Between Diagnostic Modalities</title><p id="Par25">We first verified that the CAP score was significantly higher when steatosis was present for LB (<italic toggle="yes">t</italic>(41)&#8201;=&#8201;4.9, 95% CI 45.9&#8211;110.9), MRI (<italic toggle="yes">t</italic>(109)&#8201;=&#8201;6.4, 95% CI 50.4&#8211;95.3), and US (<italic toggle="yes">t</italic>(366)&#8201;=&#8201;9.5, 95% CI 51.4&#8211;78.2) (Supplementary Fig.&#160;8). Several patients had more than one US, MRI, and LB available (Supplementary table 2). When a patient had multiple studies available, we compared imaging and LB data for the presence or absence of HS. US and LB (<italic toggle="yes">&#312;</italic>(50)&#8201;=&#8201;0.47, 95% CI 0.47&#8211;0.72) and US and MRI (<italic toggle="yes">&#312;</italic>(104)&#8201;=&#8201;0.45, 95% CI 0.6&#8211;0.75) had moderate concordance, while MRI and LB exhibited fair/low concordance (<italic toggle="yes">&#312;</italic>(50)&#8201;=&#8201;0.22, 95% CI &#8722;&#160;0.25 to 0.69), attributable to a low count (<italic toggle="yes">n</italic>&#8201;=&#8201;14) (Supplementary Fig.&#160;9). As expected and as is typical of a real-world cohort, the majority of our data had HS arbitrated by radiographic evidence (either MRI or US, <italic toggle="yes">n</italic>&#8201;=&#8201;349; 87%) and fewer by LB (<italic toggle="yes">n</italic>&#8201;=&#8201;54; 13%).</p></sec><sec id="Sec23"><title>ROC Analysis and CAP Threshold Selection</title><p id="Par26">The area under the curve for the CAP scores predicting NAFLD as defined by HS on US, MRI, or LB was 75.5% (95% CI 70.7&#8211;80.3%) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). The Youden cut-off was 273.5&#160;dB/m, resulting in sensitivity of 74.8%, specificity of 68.9%, PPV of 75.4%, and NPV of 68.2%. We additionally assessed the CAP threshold using only the sub-group of patients who had a LB and MRI (without US), given their higher sensitivity in detecting HS. We found that a total of 155 patients had either a LB or MRI. Similarly to the group of patients with US, we found that the optimal CAP threshold was 272&#160;dB/m (Supplementary Fig.&#160;10). Alternate CAP cut-offs and their resulting sensitivity, specificity, PPV, and NPV values are provided in Supplementary table 4.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Receiver operating characteristic curve replicating CAP scores that suggest tests positive for hepatic steatosis (<italic toggle="yes">n</italic>&#8201;=&#8201;403)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="10620_2023_8043_Fig4_HTML.jpg"/></fig></p></sec></sec></sec><sec id="Sec24"><title>Discussion</title><p id="Par27">In this study, we developed a novel HS clinical predictive algorithm that can be used to screen Veterans in primary care and endocrinology clinics. Our model has key features that are worth emphasizing: (1) it uses clinically reasonable and readily available predictors, allowing ease of implementation; (2) it is the first to utilize the VCTE CAP score in its development in a Veteran population; (3) it is validated in an independent Veteran cohort; and (4) it is in keeping with growing efforts to develop clinical care pathways that can capture NAFLD patients early, before they develop late complications, especially as most cirrhosis related to NAFLD is found incidentally. [<xref ref-type="bibr" rid="CR29">29</xref>]</p><p id="Par28">In the context of linkage to care, we envision embedding our predictive model in EHR to identify patients at risk for NAFLD in primary care clinics. Patients who are predicted to have NAFLD based on the predicted CAP score can subsequently be risk stratified by FIB-4, which can guide downstream assessment by VCTE and referral to sub-specialty care. FIB-4 has been shown to have a low accuracy when applied to the general population and has the potential to overestimate the risk of liver disease and cause over-referrals to sub-specialty care [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. While VCTE is more accurate, its general use would hinder clinics without this technology and likely drive health care costs given it has been shown not be cost effective as an initial non-invasive test for NAFLD assessment [<xref ref-type="bibr" rid="CR19">19</xref>]. There is therefore a gap in developing a simple clinical tools, such as ours, to bridge non-invasive testing where VCTE may not be available, as recommended by the society guidelines. [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</p><p id="Par29">Variable selection was methodical and informed by NAFLD biologic plausibility and also ease of clinical use. Noureddin and colleagues predicted the prevalence of NAFLD based on CAP scores using machine learning methods in the National Health And Nutrition Examination Survey cohort [<xref ref-type="bibr" rid="CR33">33</xref>]. In their agnostic approach, they identified all of our predefined covariables, affirming the validity of our model [<xref ref-type="bibr" rid="CR33">33</xref>]. However, they identified waist circumference as a significant predictor, which is not collected in routine clinical care, as evidenced by the lack of waist circumference measurements in our cohort and which therefore limits the clinical applicability of their model. Previous algorithms, such as the fatty liver index, the NAFLD-Liver Fat Score, the NAFLD Screening score, and the ALD/NAFLD Index, are also similarly limited because they utilize variables such as waist circumference, insulin level, uric acid, and haptoglobin which are not routinely collected by primary care [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. By contrast, our <inline-formula id="IEq7"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\widehat{\mathrm{CAP}}$$\end{document}</tex-math><mml:math id="M24"><mml:mover accent="true"><mml:mi mathvariant="normal">CAP</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_Article_IEq7.gif"/></alternatives></inline-formula> model can be calculated for any Veteran evaluated in primary or sub-specialty clinics without requiring additional dedicated bloodwork or clinic encounters.</p><p id="Par30">In addition to predicting a CAP threshold, identifying one that diagnoses HS can simplify clinical decision-making. We noted heterogeneity in previously published CAP thresholds that may be attributable to population-specific factors or the method by which HS was detected [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. We therefore opted to determine an internal VA CAP threshold rather than using historical cut-offs. Although LB remains the gold standard in the spectrum of NAFLD and NASH, few are conducted clinically. The use of LB to select NAFLD cases also introduces selection bias because a very small, narrow subset of patients with NAFLD are, in fact, biopsied. To achieve more real-world applicability, our study incorporated imaging modalities to arbitrate the diagnosis of steatosis. Previous investigation into the sensitivity and specificity of US and MRI in HS detection guided our approach [<xref ref-type="bibr" rid="CR25">25</xref>]. While, US is the most commonly used method in real-world practice, as evidenced by our findings, the sensitivity for HS detection is lower when&#8201;&lt;&#8201;30% [<xref ref-type="bibr" rid="CR25">25</xref>]. We found that our CAP score findings in Veterans are concordant with recent VHA NAFLD Consensus Guidelines [<xref ref-type="bibr" rid="CR38">38</xref>], which were guided by expert opinion.</p><p id="Par31">In our proposed score, self-identified Black race was a negative predictor, while Hispanic ethnicity was a positive predictor of NAFLD. This is consistent with prior large genetic and epidemiologic studies on population-specific prevalence of NAFLD [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. It is increasingly recognized that differences in epidemiology, natural history, and outcomes according to race and ethnicity may at least partially reflect underlying unmeasured social and structural determinants of health [<xref ref-type="bibr" rid="CR40">40</xref>]. The inclusion of race and ethnicity in our clinical score can serve to indirectly measure these influences in addition to any potentially unknown hereditary factors which contribute to NAFLD risk, and as our data show, can improve prediction of CAP score and NAFLD risk overall.</p><p id="Par32">Our study is not without limitations including its retrospective nature and single-center study population. There is a selection bias of our cohort as it mainly consists of patients evaluated in sub-specialty care, where the vast majority of VCTE are ordered. We also recognize that patients with &#8220;burnt-out&#8221; NASH may not have steatosis, potentially precluding them from being identified, although we found that 51% of our cohort with kPa&#8201;&#8805;&#8201;20 still had elevated CAP scores. Finally, the population is predominantly male and may not be generalizable to non-VA populations but performs well within Veterans, where VA-specific scores are needed.</p><p id="Par33">NAFLD remains underdiagnosed [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>], limiting our appreciation of the true disease burden and therefore, our ability to tackle it most effectively: at an early stage, when primary prevention can avert or delay complications. In line with the recent NAFLD Consensus Statement and society guidelines advocating for early identification [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], we propose that incorporating our predictive algorithm in VHA EHR would simplify the identification of at-risk Veterans in primary care and endocrinology clinics, who can subsequently be risk stratified for advanced fibrosis by non-invasive tests [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. This would provide an opportunity to implement preventative interventions including weight loss counseling, nutrition referral, and initiation of structured exercise programs which are available in VAHCS [<xref ref-type="bibr" rid="CR46">46</xref>]. Future work will focus on validating the predictive model prospectively in Veterans, while quality improvements measures in NAFLD clinical care pathways and engagement of key stakeholders are ongoing.</p></sec><sec sec-type="supplementary-material"><sec id="Sec25"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 8 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file2 (PDF 223 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file3 (PDF 24 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file4 (PDF 21 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM5_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file5 (PDF 25 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM6_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file6 (PDF 9 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM7_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file7 (PDF 94 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM8_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file8 (PDF 13 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM9_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file9 (PDF 89 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10620_2023_8043_MOESM10_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file10 (PDF 21 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We also would like to acknowledge BioRender which was used for the graphical abstract.</p></ack><notes notes-type="author-contribution"><title>Author&#8217;s contribution</title><p>Study concept and design (JNB, SB, MS, AAP, NP); literature review (SB, RS, AL, JNB, AAP, TSD, MS, NP); data acquisition and analysis (SB, RS, AL, FH, NP, JK, JNB); drafting of the manuscript (all authors); critical revision of the manuscript for important intellectual content (all authors); and study supervision (JNB, MS).</p></notes><notes notes-type="funding-information"><title>Funding</title><p>JNB is supported by the NIH National Center for Advancing Translational Sciences (UL1TR001881), the Liver Basic Research Center at the University of California, Los Angeles, and the&#160;Veterans Affairs Career Development Award (1IK2CX002593-01).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>De-identified data will be made available upon reasonable requests.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par34">None of the authors disclose any conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estes</surname><given-names>C</given-names></name><name name-style="western"><surname>Razavi</surname><given-names>H</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><etal/></person-group><article-title>Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">28802062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29466</pub-id><pub-id pub-id-type="pmcid">PMC5767767</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwal</surname><given-names>F</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans</article-title><source>Clin Gastroenterol Hepatol</source><year>2016</year><volume>14</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">26291667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2015.08.010</pub-id><pub-id pub-id-type="pmcid">PMC4918764</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahfood Haddad</surname><given-names>T</given-names></name><name name-style="western"><surname>Hamdeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanmanthareddy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis</article-title><source>Diabetes Metab Syndr</source><year>2017</year><volume>11</volume><fpage>S209</fpage><lpage>S216</lpage><pub-id pub-id-type="pmid">28017631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dsx.2016.12.033</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Csermely</surname><given-names>A</given-names></name><name name-style="western"><surname>Petracca</surname><given-names>G</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis</article-title><source>Lancet Gastroenterol Hepatol</source><year>2021</year><volume>6</volume><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">34555346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(21)00308-3</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Petracca</surname><given-names>G</given-names></name><name name-style="western"><surname>Beatrice</surname><given-names>G</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies</article-title><source>Gut</source><year>2021</year><volume>71</volume><fpage>778</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">33685968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2021-324191</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>HD</given-names></name><name name-style="western"><surname>Niezen</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis</article-title><source>Dig Dis Sci</source><year>2021</year><volume>67</volume><fpage>4222</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-021-07228-3</pub-id><pub-id pub-id-type="pmcid">PMC10697075</pub-id><pub-id pub-id-type="pmid">34417922</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Stepanova</surname><given-names>M</given-names></name><name name-style="western"><surname>Ong</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates</article-title><source>Clin Gastroenterol Hepatol</source><year>2019</year><volume>17</volume><fpage>e3</fpage><pub-id pub-id-type="pmid">29908364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2018.05.057</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hester</surname><given-names>D</given-names></name><name name-style="western"><surname>Golabi</surname><given-names>P</given-names></name><name name-style="western"><surname>Paik</surname><given-names>J</given-names></name><etal/></person-group><article-title>Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality</article-title><source>J Clin Gastroenterol.</source><year>2019</year><volume>54</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0000000000001172</pub-id><pub-id pub-id-type="pmid">30672817</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>JE</given-names></name><etal/></person-group><article-title>The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>328</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">28714183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29367</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barritt</surname><given-names>AS</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study</article-title><source>Hepatol Commun</source><year>2021</year><volume>5</volume><fpage>938</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">34141981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep4.1689</pub-id><pub-id pub-id-type="pmcid">PMC8183178</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwal</surname><given-names>F</given-names></name><name name-style="western"><surname>Shubrook</surname><given-names>JH</given-names></name><name name-style="western"><surname>Adams</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease</article-title><source>Gastroenterology</source><year>2021</year><volume>161</volume><fpage>1657</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">34602251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.07.049</pub-id><pub-id pub-id-type="pmcid">PMC8819923</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasso</surname><given-names>M</given-names></name><name name-style="western"><surname>Audiere</surname><given-names>S</given-names></name><name name-style="western"><surname>Kemgang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy</article-title><source>Ultrasound Med Biol</source><year>2016</year><volume>42</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">26386476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ultrasmedbio.2015.08.008</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>WK</given-names></name><name name-style="western"><surname>Nik Mustapha</surname><given-names>NR</given-names></name><name name-style="western"><surname>Wong</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population</article-title><source>United European Gastroenterol J</source><year>2017</year><volume>5</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">28405325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2050640616646528</pub-id><pub-id pub-id-type="pmcid">PMC5384552</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Ledinghen</surname><given-names>V</given-names></name><name name-style="western"><surname>Wong</surname><given-names>GL</given-names></name><name name-style="western"><surname>Vergniol</surname><given-names>J</given-names></name><etal/></person-group><article-title>Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease</article-title><source>J Gastroenterol Hepatol</source><year>2016</year><volume>31</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">26514665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.13219</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>BG</given-names></name><name name-style="western"><surname>Park</surname><given-names>WY</given-names></name><name name-style="western"><surname>Park</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0182784</fpage><pub-id pub-id-type="pmid">28813448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0182784</pub-id><pub-id pub-id-type="pmcid">PMC5557594</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlas</surname><given-names>T</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>D</given-names></name><name name-style="western"><surname>Garnov</surname><given-names>N</given-names></name><etal/></person-group><article-title>Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e91987</fpage><pub-id pub-id-type="pmid">24637477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0091987</pub-id><pub-id pub-id-type="pmcid">PMC3956815</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SU</given-names></name><etal/></person-group><article-title>Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0157358</fpage><pub-id pub-id-type="pmid">27284700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0157358</pub-id><pub-id pub-id-type="pmcid">PMC4902201</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar-Gomez</surname><given-names>E</given-names></name><name name-style="western"><surname>Vuppalanchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Gawrieh</surname><given-names>S</given-names></name><etal/></person-group><article-title>CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><fpage>1241</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">36626638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HEP.0000000000000023</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Udompap P, Therneau TM, Canning RE, et al. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology 2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.32739</pub-id><pub-id pub-id-type="pmid">35989502</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>N</given-names></name><name name-style="western"><surname>Blais</surname><given-names>P</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>40</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">25155259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.12923</pub-id><pub-id pub-id-type="pmcid">PMC5331854</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Franchis</surname><given-names>R</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name><name name-style="western"><surname>Garcia-Tsao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Baveno VII - Renewing consensus in portal hypertension</article-title><source>J Hepatol</source><year>2021</year><volume>76</volume><fpage>959</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">35120736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2021.12.022</pub-id><pub-id pub-id-type="pmcid">PMC11090185</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>C</given-names></name><name name-style="western"><surname>Hodson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice</article-title><source>Postgrad Med J</source><year>2013</year><volume>89</volume><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">23924687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/postgradmedj-2012-131640</pub-id><pub-id pub-id-type="pmcid">PMC3841754</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>JX</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>S</given-names></name><name name-style="western"><surname>Niu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e95776</fpage><pub-id pub-id-type="pmid">24755824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0095776</pub-id><pub-id pub-id-type="pmcid">PMC3995722</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romeo</surname><given-names>S</given-names></name><name name-style="western"><surname>Kozlitina</surname><given-names>J</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>1461</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">18820647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.257</pub-id><pub-id pub-id-type="pmcid">PMC2597056</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohte</surname><given-names>AE</given-names></name><name name-style="western"><surname>van Werven</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bipat</surname><given-names>S</given-names></name><etal/></person-group><article-title>The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis</article-title><source>Eur Radiol</source><year>2011</year><volume>21</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">20680289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-010-1905-5</pub-id><pub-id pub-id-type="pmcid">PMC2995875</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>JL</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults</article-title><source>Dig Dis Sci</source><year>2021</year><volume>67</volume><fpage>3340</fpage><lpage>3355</lpage><pub-id pub-id-type="pmid">34173916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-021-07124-w</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonder</surname><given-names>A</given-names></name><name name-style="western"><surname>Afdhal</surname><given-names>N</given-names></name></person-group><article-title>Utilization of FibroScan in clinical practice</article-title><source>Curr Gastroenterol Rep</source><year>2014</year><volume>16</volume><fpage>372</fpage><pub-id pub-id-type="pmid">24452634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11894-014-0372-6</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Stepanova</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">30144554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2018.08.013</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertot</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>GP</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma</article-title><source>Hepatol Commun</source><year>2017</year><volume>1</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">29404433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep4.1018</pub-id><pub-id pub-id-type="pmcid">PMC5747027</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugiyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Kurisu</surname><given-names>AEB</given-names></name><etal/></person-group><article-title>Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups</article-title><source>BMC Gastroenterol</source><year>2022</year><volume>22</volume><fpage>241</fpage><pub-id pub-id-type="pmid">35562658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-022-02290-1</pub-id><pub-id pub-id-type="pmcid">PMC9101936</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graupera</surname><given-names>I</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>M</given-names></name><name name-style="western"><surname>Serra-Burriel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><fpage>e6</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.12.034</pub-id><pub-id pub-id-type="pmid">34971806</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinella</surname><given-names>ME</given-names></name><name name-style="western"><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>MS</given-names></name><etal/></person-group><article-title>AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease</article-title><source>Hepatology</source><year>2023</year><volume>77</volume><fpage>1797</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">36727674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HEP.0000000000000323</pub-id><pub-id pub-id-type="pmcid">PMC10735173</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noureddin</surname><given-names>M</given-names></name><name name-style="western"><surname>Ntanios</surname><given-names>F</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>D</given-names></name><etal/></person-group><article-title>Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017&#8211;2018 transient elastography data and application of machine learning</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><fpage>1537</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">35365931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep4.1935</pub-id><pub-id pub-id-type="pmcid">PMC9234676</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedogni</surname><given-names>G</given-names></name><name name-style="western"><surname>Bellentani</surname><given-names>S</given-names></name><name name-style="western"><surname>Miglioli</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population</article-title><source>BMC Gastroenterol</source><year>2006</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type="pmid">17081293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-230X-6-33</pub-id><pub-id pub-id-type="pmcid">PMC1636651</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotronen</surname><given-names>A</given-names></name><name name-style="western"><surname>Peltonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hakkarainen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">19524579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2009.06.005</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petroff</surname><given-names>D</given-names></name><name name-style="western"><surname>Blank</surname><given-names>V</given-names></name><name name-style="western"><surname>Newsome</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis</article-title><source>Lancet Gastroenterol Hepatol</source><year>2021</year><volume>6</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">33460567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(20)30357-5</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eddowes</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Sasso</surname><given-names>M</given-names></name><name name-style="western"><surname>Allison</surname><given-names>M</given-names></name><etal/></person-group><article-title>Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><fpage>1717</fpage><lpage>1730</lpage><pub-id pub-id-type="pmid">30689971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.01.042</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Consensus Recommendations for the Diagnosis and Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Multidisciplinary Approach for the Veterans Health Administration Version 1.0. 2022:1&#8211;79.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Benhammou JN, Lin J, Hussain SK, et al. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.20517/2394-5079.2020.16</pub-id><pub-id pub-id-type="pmcid">PMC7367098</pub-id><pub-id pub-id-type="pmid">32685690</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddique</surname><given-names>SM</given-names></name><name name-style="western"><surname>May</surname><given-names>FP</given-names></name></person-group><article-title>Race-Based Clinical Recommendations in Gastroenterology</article-title><source>Gastroenterology</source><year>2022</year><volume>162</volume><fpage>408</fpage><lpage>414.e2</lpage><pub-id pub-id-type="pmid">34890599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2021.12.234</pub-id><pub-id pub-id-type="pmcid">PMC10115149</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R</given-names></name><name name-style="western"><surname>Fraysse</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data</article-title><source>Aliment Pharmacol Ther</source><year>2020</year><volume>51</volume><fpage>1149</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">32372515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.15679</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blais</surname><given-names>P</given-names></name><name name-style="western"><surname>Husain</surname><given-names>N</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease is underrecognized in the primary care setting</article-title><source>Am J Gastroenterol</source><year>2015</year><volume>110</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">24890441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2014.134</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>AP</given-names></name><name name-style="western"><surname>Desai</surname><given-names>AP</given-names></name><name name-style="western"><surname>Bajpai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gaps in recognition and evaluation of incidentally identified hepatic steatosis</article-title><source>Dig Dis Sci</source><year>2015</year><volume>60</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">25190263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-014-3346-5</pub-id><pub-id pub-id-type="pmcid">PMC4385713</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarus</surname><given-names>JV</given-names></name><name name-style="western"><surname>Mark</surname><given-names>HE</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>QM</given-names></name><etal/></person-group><article-title>Advancing the global public health agenda for NAFLD: a consensus statement</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2022</year><volume>19</volume><fpage>60</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">34707258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-021-00523-4</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schattenberg</surname><given-names>JM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>H</given-names></name><etal/></person-group><article-title>A multistakeholder approach to innovations in NAFLD care</article-title><source>Commun Med (Lond)</source><year>2023</year><volume>3</volume><fpage>1</fpage><pub-id pub-id-type="pmid">36596859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43856-022-00228-y</pub-id><pub-id pub-id-type="pmcid">PMC9810711</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>CM</given-names></name><name name-style="western"><surname>Turner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Identifying and Treating Nonalcoholic Fatty Liver Disease</article-title><source>Fed Pract</source><year>2019</year><volume>36</volume><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">30766414</pub-id><pub-id pub-id-type="pmcid">PMC6366580</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>